Robert Leo Murphy
Murphy, Robert L., 1950-
Murphy, Robert L.
VIAF ID: 21478906 (Personal)
Permalink: http://viaf.org/viaf/21478906
Preferred Forms
-
- 100 1 _ ‡a Murphy, Robert L. ‡d 1950-
-
- 100 1 _ ‡a Murphy, Robert L., ‡d 1950-
- 100 0 _ ‡a Robert Leo Murphy
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
Contemporary diagnosis and management of HIV/AIDS infections, c1997: | |
Individualized antiretroviral therapeutic approaches: less can be more | |
Influence of filgrastim | |
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection | |
Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG | |
Introduction | |
Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. | |
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir | |
Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia | |
Long-Term Follow-Up of HIV-Infected Individuals Who Have Significant Increases in CD4+ Cell Counts during Antiretroviral Therapy | |
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study | |
Management of antiretroviral failure and resistance in developing countries | |
Middle East and North Africa SARS-CoV-2 Surveillance: A Longitudinal Trend Analysis | |
Missed Opportunities for Prevention of Mother-to-Child Transmission of HIV (PMTCT) in Ibadan, Southwest Nigeria | |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen | |
Molecular identification of Mycobacterium bovis from cattle and human host in Mali: expanded genetic diversity | |
The most frequent Mycobacterium tuberculosis complex families in mali (2006-2016) based on spoligotyping. | |
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings | |
Mycobacterium africanum (Lineage 6) shows slower sputum smear conversion on tuberculosis treatment than Mycobacterium tuberculosis (Lineage 4) in Bamako, Mali | |
Mycobacterium tuberculosis and Mycobacterium africanum in stools from children attending an immunization clinic in Ibadan, Nigeria. | |
Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults | |
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile | |
Les nouvelles molécules anti-VIH : la place du raltégravir | |
Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results | |
Off. ABMS dir. of bd. cert. med. spec., 1999: | |
Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings. | |
Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria | |
Outcomes for therapeutic vaccines trials | |
Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial | |
The pavia consensus statement | |
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. | |
Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients | |
Poor immune status and systemic disease are independently associated with mortality in AIDS-related Kaposi Sarcoma in Nigeria | |
Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose. | |
Predicting 3-day and 7-day outcomes of weaning from mechanical ventilation. | |
Predictors of atypical squamous cell of undetermined significance cervical cytology with high-risk human papilloma virus genotypes | |
Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma | |
Presentation and survival in patients with hematologic malignancies in Jos, Nigeria: A retrospective cohort analysis. | |
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients | |
Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients | |
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness | |
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 × 106/l | |
Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression | |
Quantification of human immunodeficiency virus type 1 tat mRNA as a marker for assessing the efficacy of antiretroviral therapy. | |
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects | |
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients | |
The reply | |
Reviving protease inhibitors: new data and more options. | |
Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy | |
Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3 | |
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients | |
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study | |
Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients | |
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. | |
Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3 | |
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial | |
Salvage Therapy with Clindamycin/Primaquine for Pneumocystis carinii Pneumonia | |
Screening new tuberculosis patients in Mali for rifampicin resistance at 2months | |
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels | |
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). | |
Simultaneous diagnosis of tuberculous and non-tuberculous mycobacterial diseases: Time for a better patient management | |
Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection | |
Stability of HIV RNA in plasma specimens stored at different temperatures | |
Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for Helicobacter pylori and Mycobacterium tuberculosis in Bamako, Mali | |
Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. | |
Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort | |
Switch studies: a review. | |
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. | |
Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial | |
Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. | |
Transient Viremia in HIV-Infected Patients and Use of Plasma Preparation Tubes | |
Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Ségou and Bamako, Mali | |
Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings | |
Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial | |
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection | |
Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study | |
Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection | |
Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis | |
Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management | |
Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials | |
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study | |
Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group | |
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases | |
ভূমিকা | |
সংশোধন |